Novavax (NVAX) Stock Is Up Big On COVID-19 Vaccine Advancements

Novavax NVAX Stock News

Novavax, Inc. (NASDAQ: NVAX) is making a run for the top in the market this morning, and for good reason. The company announced news with regard to its progress in the development of a vaccine for the novel coronavirus. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

NVAX Announces Progress In COVID-19 Vaccine Development

In the press release, Novavax said that it has identified a coronavirus vaccine candidate. The candidate, known as NVX-CoV2373 is a stable, prefusion protein made with the company’s proprietry nanoparticle technology.

In the release, the company said that it plans on initiating a first-in-human trial as early as next month. Importantly, the company’s proprietary Matrix-M adjuvant will be incorporated with NVX-CoV2373. The Matrix-M adjuvant will be used to enhance immune responses and stimulate high levels of naturalizing antibodies.

NVAX said that its candidate has shown to be highly immunogenic in animal models. This was seen by measuring spike protein-specific antibodies. These are the antibodies that block the binding of the spike protein to the receptor. The company also saw an increase in wild-type virus neutralizing antibodies.

In a statement, Gregory Glenn, M.D., President of Research and Development at NVAX, had the following to offer:

Our scientists identified an ideal vaccine candidate selected from a number of constructs and, in partnership with Dr. Matthew Frieman, demonstrated that NVX-CoV2373 produces high levels of neutralizing antibodies against SARS-CoV-2 in animal studies. In addition, we have worked closely with our colleagues at Emergent BioSolutions to transfer our production technology that allows the manufacture of GMP vaccine for clinical trials. With preliminary CEPI funding, these heroic efforts, combined with the candidate’s excellent early results, put us in position to have preliminary human data in July.

The above statement was followed up by Stanley C. Erck, President and CEO at NVAX. Here’s what he had to say:

Because of the tireless efforts and commitment of the Novavax team and our collaborators, we are preparing to initiate the NVX-CoV2373 Phase 1 trial in mid-May, weeks ahead of schedule. This progress demonstrates the ability of our recombinant nanoparticle technology to rapidly create vaccine candidates for emerging viruses like SARS-CoV-2. In addition, the performance of NVX-CoV2373 in multiple preclinical studies and testing gives us increased confidence in its potential to protect against COVID-19 disease.

This Is Exciting News

As the COVID-19 pandemic continues to spread around the world, the demand for a vaccine is only growing. Novavax is one of the companies that are leading the charge in the development of a viable vaccine to protect consumers from the virus.

While there are plenty of competitors looking to develop a COVID-19 vaccine, few have anything tangible. Even fewer have anything that’s ready for the clinic. Due to the announcement today, NVAX is quickly becoming one of the frontrunners in the race.

Of course, those that develop the first viable vaccines have an opportunity to see dramatic revenue growth. With NVAX falling cleanly in that category, this is a stock that’s well worth watching.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.